Related Experiment Video

Updated: May 20, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?

Elisa Giovannetti1, Francesca Toffalorio, Tommaso De Pas

  • 1Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Pharmacogenomics
|July 31, 2012
PubMed

Insights

Pharmacogenetics can personalize cancer chemotherapy by matching drugs to a patient's genetic profile for better outcomes. Further research and validation are needed to optimize this approach for non-small-cell lung cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Pharmacogenetics offers potential for tailoring chemotherapy to individual genetic profiles to maximize efficacy and minimize toxicity.
  • Non-small-cell lung cancer (NSCLC) research has proposed biomarkers for drug sensitivity/resistance, but results are often contradictory.

Purpose of the Study:

  • To review the current status and future directions of pharmacogenetics in optimizing cancer chemotherapy, particularly for NSCLC.
  • To highlight the need for validation of biomarkers in prospective trials and the importance of understanding complex gene regulation.

Main Methods:

  • Review of existing literature on pharmacogenetics in cancer chemotherapy.
  • Discussion of proposed biomarkers for platinum compounds, gemcitabine, taxanes, and pemetrexed in NSCLC.
  • Exploration of factors influencing genotype-phenotype relationships, including miRNAs and pharmacokinetic/pharmacodynamic interactions.

Main Results:

  • Several potential pharmacogenetic biomarkers for NSCLC chemotherapy have been identified but require validation.
  • Optimization and standardization of technical procedures are crucial for reliable pharmacogenetic testing.
  • Genome-wide studies are emerging as a powerful tool to overcome limitations of traditional candidate gene approaches.

Conclusions:

  • Pharmacogenetic strategies hold promise for personalized cancer treatment, but require rigorous validation in large-scale clinical trials.
  • Further research into gene function regulation, miRNAs, and drug interaction pathways is essential for clinical implementation.
  • The field is moving towards comprehensive genomic approaches for more effective chemotherapy selection.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...